Immix Biopharma, INC. (IMMX) — 10-Q Filings

10-Q Filings (6)

• Immix Biopharma's Losses Widen Amid Rising R&D Costs — Nov 7, 2025 Risk: high
  Immix Biopharma, Inc. reported a net loss of $18,750,783 for the nine months ended September 30, 2025, an increase from a net loss of $16,886,309 for the same p
• Immix Biopharma's Q2 Loss Widens Amid R&D Spend — Aug 8, 2025 Risk: high
  Immix Biopharma, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, as the company remains in th
• Immix Biopharma Files Q1 2025 10-Q — May 8, 2025 Risk: medium
  Immix Biopharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company, focused on pharmaceutical preparations, reported financial data for the
• Immix Biopharma Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Immix Biopharma, Inc. filed its 10-Q for the period ending September 30, 2024. The company is involved in the pharmaceutical preparations industry, with its pri
• Immix Biopharma Files 10-Q for Q2 2024 — Aug 12, 2024 Risk: medium
  Immix Biopharma, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results for the second quarter and the first six mo
• Immix Biopharma, Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
  Immix Biopharma, Inc. (IMMX) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Immix Biopharma, Inc. filed a 10-Q report for the quarterly period end

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX